2008
Stable Long-Term Donor Engraftment following Reduced-Intensity Hematopoietic Cell Transplantation for Sickle Cell Disease
Krishnamurti L, Kharbanda S, Biernacki M, Zhang W, Baker K, Wagner J, Wu C. Stable Long-Term Donor Engraftment following Reduced-Intensity Hematopoietic Cell Transplantation for Sickle Cell Disease. Transplantation And Cellular Therapy 2008, 14: 1270-1278. PMID: 18940682, DOI: 10.1016/j.bbmt.2008.08.016.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAnemia, Sickle CellChildCyclosporineFemaleGraft SurvivalGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansImmunosuppressive AgentsLiving DonorsMaleMycophenolic AcidMyeloablative AgonistsSiblingsTransplantation ChimeraTransplantation ConditioningTransplantation, HomologousConceptsHematopoietic stem cell transplantationSickle cell diseaseRIC regimenCell transplantationCell diseaseEfficacy of HSCTHigh-risk sickle cell diseaseReduced-Intensity Hematopoietic Cell TransplantationAllogeneic hematopoietic stem cell transplantationReduced-intensity conditioning regimensEquine antithymocyte globulinHost disease (GVHD) prophylaxisTotal lymphoid irradiationAcceptable therapeutic optionHematopoietic cell transplantationGroup of patientsStem cell transplantationAntithymocyte globulinLymphoid irradiationConditioning regimenMycophenolate mofetilConditioning regimensDisease prophylaxisDonor engraftmentTherapeutic options
2007
Use of Rituximab for Refractory Immune Cytopenias Associated with Autoimmune Lymphoproliferative Syndrome (ALPS).
Dale J, Price S, Tretler J, Aldridge P, Montague S, Davis J, Gill F, Hartman K, Stork L, Gnarra D, Krishnamurti L, Puck J, Fleisher T, Rao V. Use of Rituximab for Refractory Immune Cytopenias Associated with Autoimmune Lymphoproliferative Syndrome (ALPS). Blood 2007, 110: 1319. DOI: 10.1182/blood.v110.11.1319.1319.Peer-Reviewed Original ResearchAutoimmune lymphoproliferative syndromeALPS patientsMycophenolate mofetilRituximab therapyDouble-negative T lymphocytesALPS phenotypeNegative T lymphocytesUse of rituximabCompletion of therapyRed cell transfusionAdult male patientsNIH Clinical CenterLong-term riskDurable normalizationPneumococcal sepsisPrednisone pulsesRefractory ITPRituximab infusionRituximab useWeekly vincristineCell transfusionHepatitis CImmune thrombocytopeniaPalpable spleenPolysaccharide vaccine
2005
Unrelated Cord Blood Transplantation (UCBT) in Children with Sickle Cell Disease (SCD): US Centers Experience.
Adamkiewicz T, Haight A, Mazur M, Baker K, Szabolcs P, Kedar A, Chiang K, Krishnamurti L, Wagner J, Wingard J, Yeager A. Unrelated Cord Blood Transplantation (UCBT) in Children with Sickle Cell Disease (SCD): US Centers Experience. Blood 2005, 106: 2044. DOI: 10.1182/blood.v106.11.2044.2044.Peer-Reviewed Original ResearchUnrelated cord blood transplantationAnti-thymocyte globulinSickle cell diseaseHigh-risk sickle cell diseaseReduced-intensity regimensMycophenolate mofetilYo maleDonor engraftmentAutologous reconstitutionDonor originReduced-intensity preparative regimenUnrelated cord blood unitsAcute grade IIIConventional myeloablative regimensExtensive chronic GVHDGrade 1 mucositisGrade III mucositisGrade IV GVHDMyeloablative preparative regimensParainfluenza 3 infectionSevere acute GVHDSustained donor engraftmentTotal lymphoid irradiationTransfusion-induced alloimmunizationElevated liver enzymes